Accuray ARAYAccuray IncorporatedBATS:ARAYSimeonNikolaev-investAccuray (ARAY) is currently the antithesis of a high-quality growth stock. It fails all elite screens: Gross Margins at 23.5% (vs 80% target), Negative ROE of -32%, and shrinking revenues (-12% YoY). The balance sheet is heavily leveraged with a Debt/Equity ratio near 2.9 and a distressing Altman Z-Score of 1.4. However, there is a massive divergence between financial performance and insider sentiment. Directors and the CEO have been aggressive buyers in February 2026, with zero insider sales in the last 6 months. Trading at a deep discount to its DCF fair value ($2.53 vs $0.54 market price), ARAY is a high-risk turnaround play. Unless revenue growth hits the 30% mark and margins stabilize, this remains a speculative bet on management's ability to execute a pivot